Pulmonx (LUNG) Expected to Announce Earnings on Wednesday

Core Viewpoint - Pulmonx reported better-than-expected quarterly earnings, with a revenue of $21.50 million, surpassing analyst estimates of $20.78 million, and an EPS of ($0.34), exceeding the consensus estimate of ($0.40) by $0.06 [1] Financial Performance - The company had a negative return on equity of 77.58% and a negative net margin of 61.91% [1] - The stock opened at $1.45, with a market cap of $59.81 million, a PE ratio of -1.03, and a beta of 0.07 [2] - The fifty-day simple moving average is $2.04, and the 200-day simple moving average is $1.83 [2] - The stock has a fifty-two week low of $1.31 and a high of $9.37 [2] Analyst Ratings - Weiss Ratings restated a "sell (e+)" rating, while Lake Street Capital decreased their price target from $8.00 to $4.00 with a "buy" rating [4] - D. Boral Capital reaffirmed a "buy" rating with a price objective of $14.00, and Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Currently, five analysts have rated the stock as "buy," four as "hold," and one as "sell," with an average price target of $6.81 [4] Institutional Activity - XTX Topco Ltd acquired a new stake worth about $149,000, and Norges Bank acquired a position valued at approximately $392,000 [5] - Jane Street Group LLC increased its stake by 3,328.7%, now owning 88,631 shares valued at $230,000 [5] - Bank of America Corp DE boosted its position by 556.6%, owning 481,268 shares worth $1,246,000 [5] - Institutional investors and hedge funds own 91.04% of the company's stock [5] Company Overview - Pulmonx Corporation focuses on bronchoscopic lung volume reduction for patients with severe emphysema, with its flagship product being the Zephyr® Endobronchial Valve System [6] - The Zephyr Valve received CE mark approval in Europe in 2008 and FDA approval in the U.S. in 2018, gaining adoption in leading respiratory and thoracic centers [8]